Bias by indication, of course, can never be excluded despite propensity score matching of baseline covariates, but the numbers are impressive and support the case both of metformin and/or GLP1-RA use for glycemic control in people with CRM and potential cancer issues. This evidence concerns the gene GLP1R and cancer.